Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease

In this double-blind phase II randomized controlled trial, patients with lung cancer or ≤2 oligometastatic pulmonary lesions and a concomitant diagnosis of ILD who are planned for radical Radiation Therapy (RT) will be randomized using a 2 x 2 factorial design to oral N-acetylcysteine (NAC) versus placebo, and also to short course corticosteroids versus placebo.

NCT Number	NCT05986318
Lead Sponsor	David Palma Collaborators: London Health Sciences Centre, Centre hospitalier de l'Université de Montréal (CHUM)
Conditions	Lung Cancer, Interstitial Lung Disease
Enrollment	98 participants
Start Date	2025-01-07
Primary Completion	2028-07-01 (estimated)
Study Completion	2032-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-09